OraSure Technologies, Inc. (OSUR) Q2 2026 Earnings Call Transcript
OraSure Technologies NASDAQ: OSUR reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results.
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Carrie Eglinton Manner CEO | XFRA Exchange | 68554V108 CUSIP |
| US Country | 500 Employees | 8 Jan 1998 Last Dividend | 8 Apr 1987 Last Split | 12 Nov 1986 IPO Date |
OraSure Technologies, Inc., founded in 2000 and headquartered in Bethlehem, Pennsylvania, operates globally offering a wide range of diagnostic solutions, specimen collection devices, and microbiome laboratory services. The company plays a pivotal role in public health by providing innovative products for the diagnosis of critical conditions such as HIV, hepatitis C (HCV), Ebola, and COVID-19 along with substance abuse testing. OraSure’s commitment to improving healthcare accessibility is evident in its development of both point-of-care and home diagnostic tests, catering to a diverse clientele including clinical laboratories, hospitals, public health organizations, and more. Their offerings have found international application in various sectors including healthcare, government, and environmental markets, making it a significant player in the diagnostics field.
The comprehensive range of products and services from OraSure Technologies, Inc. underscores its mission to deliver reliable and convenient diagnostic solutions:
These offerings underline OraSure Technologies, Inc.'s commitment to advancing health diagnostics, ensuring that critical health information is accessible, reliable, and timely.